Consultant Urologist Tim Dudderidge, who works with TFTC and is based at University Hospital Southampton, joins OnFocus today. Tim is an innovator in focal therapy and has coinvestigated most of the clinical trials and studies that have built the evidence base for focal therapy and advanced its adoption and practice. He has recently completed his appointment as Clinical Champion for Prostate Cancer UK, and he's here to discuss what he learned and what implications this might have for patient care.

Joining me today is Almar van Loon, Director of Customer Success at Quantib, a technology company that creates products to support radiologists using artificial intelligence. Almar has a background in clinical radiology, and has worked with Quantib since 2018 as an application specialist supporting radiologists and other clinicians on improving their workflow. One of the products Almar has worked with extensively is Quantib Prostate, which uses AI to read prostate MRI scans, and he’s here to discuss how this is impacting clinicians, and ultimately patients, in the diagnosis of prostate cancer.

https://www.quantib.com/en/solutions/quantib-prostate

Marc Laniado, Consultant Urologist at The Focal Therapy Clinic and a leading innovator in imaging led diagnostics and targeted treatments for prostate cancer, joins OnFocus to discuss prostate imaging and reporting. Marc has been a dedicated pracititoner and vocal advocate for the rights of patients to be informed about their treatment choices from his base at Frimley Health, where he is prostate cancer lead at Wexham Park Hospital. He’s here today to talk about the crucial role that imaging plays in diagnosing and treating prostate cancer, and why a minimal standard of imaging and reporting is essential to successful diagnosis and treatment.

Joining me today is Dr Rafael Sanchez-Salas, an emerging leader in the field of focal therapy for localised prostate cancer. Trained as a urologist in his native Venezuela, Dr Sanchez-Salas led research on robotic surgery and focal therapy for over ten years at the Institut Mutualiste Montsouris Paris, and is now a member of the faculty at McGill University in Montreal where he is leading research on localised prostate cancer and minimally invasive approaches to its management. Dr Sanchez-Salas discusses how the researchers and clinicians in the US and Canada are now deploying the evidence and patient experience gained in the UK and Europe to advance focal therapy.

Joining me today is Chris Lewis, founder and CEO of Chris’s Cancer Community, an influential and impactful online community of cancer patients, recoverers, and those affected by cancer. The community has a significant online following (over 35k followers on Twitter) and Chris has shared his unique and substantial knowledge on the daily experience of living with cancer with charities, government organisations and businesses both in the UK and internationally. HE is one of the most knowledgeable, insightful and honest campaigners I’ve met, and I’m delighted to chat with him today about the current state of cancer services in the UK and what members of his community are telling him about it.

https://www.chris-cancercommunity.com

@christheeagle1

This episode features Raj Nigam, Consultant Urologist at the Royal Surrey NHS Foundation Trust and the Focal Therapy Clinic. Raj  is an andrologist with a special interest in the impact of prostate cancer treatment on sexual and mental health, and has spoken several times with On Focus about age-related implications of prostate cancer treatment. He’s here today to discuss a range of issues that have evolved since the pandemic that are impacting how men with localised prostate cancer are being diagnosed and treated.

True North project on prostate cancer:

https://prostatecanceruk.org/about-us/projects-and-policies/truenth

Joining the podcast today is Alan Doherty, Clinical Director at the Birmingham Prostate Clinic, and recently voted one of the UK’s top ten prostate cancer specialists in a national poll of consultant urologists published in the Daily Mail.

Alan has been an innovator, advocate and dedicated practitioner of precision treatments for prostate cancer, and joined the Focal Therapy Clinic last year to develop his expertise in delivering focal therapy.  Having now treated a large cohort of patients with focal therapy following the Clinic’s rigorous MDT review , he’s even more positive now about the approach than he’s ever been, and joins Clare today to discuss how this experience makes him optimistic about the future of focal therapy and, most importantly, the future for men diagnosed with localised prostate cancer.

Consultant Urologist Tim Dudderidge joins OnFocus to discuss recent trends in technology and research. Tim works with the Focal Therapy Clinic and is based at University Hospital Southampton. He’s an innovator in focal therapy and has coinvestigated most of the clinical trials and studies that have built the evidence base for focal therapy and advanced its adoption and practice. Last year he was appointed as Clinical Champion for Prostate Cancer UK, which will give him even more impact on innovative clinical practice across the NHS. In this episode, Tim shares his views on some of the key issues driving practice in diagnosing and treating prostate cancer, and how this is impacting both patients and clinicians.

Joining On Focus today is Grant Evatt, a veteran army commando who now practices law in a firm he founded to specialise in personal injury cases. He has coordinated the Military Special Interest group for the Association of Personal Injury Lawyers (APIL), and is a recognised  authority in military claims. He has won millions of pounds for his injured clients and their grieving families and is much liked and respected by them, and his peers, for his exceptional client care and dedication to their cause.

Grant’s here to speak with me about his experience with prostate cancer and HIFU treatment.

Grant Evatt, Alma Law practice

https://www.almalaw.co.uk/our-people/grant-evatt

Joining On Focus today is Stuart McIntyre, Director of Marketing & Business Development at AngioDynamics, developer of a new approach to focal therapy called NanoKnife. It is currently running a clinical trial called PRESERVE, described as a Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population and which will evaluate the use of AngioDynamics’ NanoKnife System for ablation of prostate tissue as a focal therapy option for prostate cancer patients.

Stuart’s here to talk about how his company developed the NanoKnife system and what his expectations are for its adoption.

PRESERVE trial

https://www.angiodynamics.com/announcements/first-patients-treated-in-preserve-clinical-study/